RENO, Nev., Dec. 22, 2011 /PRNewswire/ -- Lifeline
Biotechnologies, Inc., (OTC Market: LLBO) announces a new
engineering contract with Synergy Technology, Inc. to focus on
device value engineering. Jim
Holmes, CEO, says, "This relationship will result in an
updated design for our breast testing device package for a current,
more cost effective technology while maintaining the product
integrity from our previous clinical trials. We expect this
will reduce the selling price significantly which will improve the
sales appeal considerably."
"Additionally, we expect that the state-of the-art technology
will result in more consistent tissue temperature data. The
Synergy Technology team understands medical device requirements and
has the experience to expedite this important process for us," adds
Holmes.
Synergy Technology, Inc.
For over 20 years, Synergy Technology has provided a
cost-effective and flexible alternative to in-house staffing by
providing deep knowledge, experience and skills in multiple design
and engineering disciplines to assist clients with product design,
product development and product life cycle management. Synergy
Technology has served over 100 product-centric companies around the
world, from start-up to global enterprises in industries that
include analytical, medical, gaming, automotive, communications,
consumer products and aerospace. Headquartered in Reno, NV. www.synergytec.com
About Lifeline Biotechnologies
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in
1994 is based in Reno, NV.
The Company has invested over $10M in
a device and process for early detection of breast tissue
abnormalities some of which are cancerous or pre-cancer.
Three patents are pending, one patent is issued and three clinical
trials with over 650 participants have been completed.
www.lbti.com
Safe Harbor: This release includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 27E of the Securities Act of 1934. Statements contained in
this release that are not historical facts may be deemed to be
forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected
or suggested herein due to certain risks and uncertainties
including, without limitation, the ability to obtain financing,
successful development of the Company's product or market
acceptance of the product and regulatory and shareholder approval
for anticipated actions.
For more information, contact:
Jim Holmes, CEO
775-326-9614
Email: Jholmes@lbti.com
SOURCE Lifeline Biotechnologies, Inc.